11:20 AM EDT, 10/07/2024 (MT Newswires) -- ViiV Healthcare said Monday it is committed to providing at least two million doses of long-acting cabotegravir for HIV pre-exposure prophylaxis to low- and middle-income countries over the next two years.

ViiV Healthcare is majority-owned by GSK (GSK) and has Pfizer ( PFE ) and Shionogi as shareholders.

The company said its available supply of cabotegravir will triple relative to 2024 as a result of this new commitment.

The rollout of the medicine is advancing at a "record pace" in Sub-Saharan Africa and lower-income countries, ViiV said. After the US Food and Drug Administration approved the drug under the brand name Apretude in December 2021, regulatory submissions have focused on countries with the highest HIV burden, the company added.

The company also said that it has signed a licensing agreement with the Medicines Patent Pool in July 2022 to support the development of generic versions of the drug.

Price: 39.03, Change: +0.20, Percent Change: +0.53